This lipid nanoformulation could enrich in the tumor niche via efficiently binding to the low–density lipoprotein receptor expressing endothelial cells, and selectively induce apoptosis of CD133+ GSCs as well as endothelial stroma cells (147). This evidence concerns the gene PROM1 and neoplasm.